SCHEMBL22340907

SCHEMBL22340907

CCCN(Cc1ccc(OC)cc1)c1ccc(C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.55
CNR1 P21554 3/20 0.55
CYP2C19 P33261 1/20 0.49
ACHE P22303 2/20 0.47
LMNA P02545 3/20 0.46
ALDH1A1 P00352 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPT P10636 2/20 0.44
TSPO P30536 1/20 0.43
USP2 O75604 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
BCHE P06276 1/20 0.42
APAF1 O14727 1/20 0.41
NR1I2 O75469 1/20 0.41
HSP90AA1 P07900 1/20 0.41
IDE P14735 1/20 0.41
UBE2N P61088 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20871176 1.00 CNR2 (0.55) CNR2CNR1CYP2C19ACHELMNA
SCHEMBL20871181 0.94 CNR2 (0.50) CNR2CNR1CYP2C19LMNAALDH1A1
SCHEMBL20871382 0.91 CNR2 (0.53) CNR2CNR1CYP2C19ACHELMNA
SCHEMBL22340421 0.91 CNR2 (0.53) CNR2CNR1CYP2C19ACHELMNA
SCHEMBL20871153 0.90 CNR2 (0.55) CNR2CNR1CYP2C19ACHELMNA
SCHEMBL22340475 0.90 CNR2 (0.55) CNR2CNR1CYP2C19ACHELMNA
SCHEMBL24455917 0.89 CYP2C19 (0.61) CNR2CNR1CYP2C19ACHELMNA
SCHEMBL11776874 0.89 CYP2C19 (0.61) CNR2CNR1CYP2C19ACHELMNA
SCHEMBL20871253 0.88 CNR2 (0.57) CNR2CNR1CYP2C19ACHELMNA
SCHEMBL22340877 0.88 CNR2 (0.57) CNR2CNR1CYP2C19ACHELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3707132-B1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES UNIV PARIS SACLAY (FR) 2024-07-17 EP disclosed
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines Universite Paris-Saclay (FR) 2021-06-15 US disclosed
US-20200255369-A1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES Universite Paris-Saclay (FR) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255369-A1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES ADH1C, ADH1A, ADH5 CNR2 1633/4885CNR1 1297/4885CYP2C19 1740/4885
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines ADH1C, PNMT, ADH1A CNR2 2182/4885CNR1 1767/4885CYP2C19 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.